Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26.
HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20 million from strategic partner Medtronic and additional investments by life sciences fund RTW.
Health Sciences 2 had about $67.7 million in its trust going into the vote after seeing 57.7% of shares redeemed in an earlier extension. Proceeds nonetheless exceeded the the transaction’s $60 million minimum cash condition.
The combined company will commence trading today on the Nasdaq under the symbol “OBIO”. Health Sciences 2 did not include warrants in its units when it IPO’d in August 2020.
The parties announced their $158 million deal with Orchestra BioMed in July 2022. New Hope, Pennsylvania-based Orchestra BioMed develops evidence-based therapeutic solutions for medical procedures that address major medical conditions, with a particular focus on cardiovascular diseases.
ADVISORS
- Jefferies LLC and Piper Sandler & Co. acted as Joint Lead Placement Agents for the Series D Financing
- Aegis Capital acted as Selling Agent.
- Jefferies LLC is acting as lead financial advisor and a capital markets advisor to Orchestra BioMed.
- Piper Sandler & Co. is acting as strategic advisor to Orchestra BioMed
- Piper Sandler & Co. is acting as a capital markets advisor to Orchestra BioMed.
- Chardan Capital Markets LLC is serving as financial and capital markets advisor to HSAC2
- Barclays Capital Inc. is serving as financial and capital markets advisor to HSAC2.
- Paul Hastings LLP is serving as legal counsel for Orchestra BioMed. Loeb & Loeb LLP is serving as legal counsel for HSAC2.
Terms Tracker for the Week Ending March 7, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. It was an extremely quiet week on the SPAC front with no IPOs pricing, but there were three new S-1 filings. There was also only...
At the SPAC of Dawn If things seem like they are accelerating fast to start 2025, that is even more so for the space sector, which had a big, and occasionally explosive, week this week. 2023 de-SPAC Intuitive Machines (NASDAQ:LUNR) landed on the moon a second time yesterday afternoon, but it may have seen its...
At the SPAC of Dawn SPACs have largely steered clear of the fintech sector, which used to be among its favorite hunting grounds of late, both due to unfavorable macro pressures and the lack of clear action on the traditional IPO side to comp to. That may soon change as buy-now-pay-later firm Klarna has confidentially...
At the SPAC of Dawn Stock market whip saws based on US government action are not likely going anywhere as President Donald Trump conceded “a little disturbance” is coming to the economy in a speech before a joint session of Congress. This pain in the short term is to be primarily the result of the...
Cal Redwood Acquisition Corp. has filed for a $200 million SPAC IPO, aiming to focus on opportunities in the TMT (Technology, Media, and Telecommunications) sector. The blank-check company intends to list on the Nasdaq under the symbol “CRAU”, offering 20,000,000 units at $10.00 each, with the trust funded at 100%. The unit structure includes a...